Dr Abou-Alfa discusses his CIO2022 abstract, "Transarterial Chemoembolization ± (Tremelimumab and Durvalumab ± Lenvatinib) in Hepatocellular Carcinoma: EMERALD-3."
Dr Abou-Alfa discusses his CIO2022 abstract, "Transarterial Chemoembolization ± (Tremelimumab and Durvalumab ± Lenvatinib) in Hepatocellular Carcinoma: EMERALD-3."
Dr Abou-Alfa discusses his...